Angle PLC Parsortix unlocks opportunities for drug discovery
2023年12月11日 - 4:00PM
RNSニュース (英語)
TIDMAGL
Angle PLC
11 December 2023
For immediate release 11 December 2023
ANGLE plc ("the Company")
USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS
OPPORTUNITIES FOR DRUG DISCOVERY
Harvested CTCs reveal gene expression profile associated with
development and progression of brain metastasis in melanoma
Researchers suggest such profiling could prove to be "pivotal"
to prescribing more targeted treatments in this setting
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is delighted to announce the publication of breakthrough
work by researchers at the University of New Mexico, US, into the
role of CTC gene expression in the progression of melanoma brain
metastasis. The researchers used the Parsortix system to harvest
CTCs for analysis and concluded that "... gene expression in CTCs
could be pivotal to prescribing more targeted treatment based on
the needs of the patient."
In this study, pre-clinical mouse models of melanoma brain
metastasis were split into four treatment groups and two cancer
drugs were tested individually and together vs. placebo. Blood
samples were analysed using the Parsortix system to harvest CTCs.
The authors found that using the two drugs together was the most
effective therapeutic regime, reducing tumour burden, metastasis
and CTC count.
This research provides further evidence of the capability of the
Parsortix system to be used for the harvesting of CTCs for analysis
in pre-clinical mouse models.
The global market for preclinical clinical research
organisations exceeded a valuation of US$ 5 billion in 2022 and is
expected to achieve a 7.5% CAGR over the next 10 years owing to
increasing R&D expenditure on early-stage development combined
with the growing number of drugs in preclinical development.
ANGLE Chief Executive Officer, Andrew Newland, commented:
"The use of CTC biomarkers in clinical trials is a rapidly
growing field enabling longitudinal monitoring of transcriptomic
and proteomic changes. ANGLE can provide pharma customers with a
complete range of services to support preclinical and clinical drug
development. This includes standardised and validated protocols for
analysing CTCs including the established techniques of IF, dPCR and
NGS, and the capability to deliver bespoke assays to identify drug
targets and ascertain therapeutic efficacy."
This peer-reviewed journal article is published in the journal
of Cancers and available at www.angleplc.com/publications .
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories in the UK and the United States. Services include
custom made assay development and clinical trial testing for
pharma.
Over 90 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASAPESNDFFA
(END) Dow Jones Newswires
December 11, 2023 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
過去 株価チャート
から 8 2024 まで 9 2024
Angle (LSE:AGL)
過去 株価チャート
から 9 2023 まで 9 2024